CIBC World Markets Inc. decreased its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 95.8% in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 9,051 shares of the medical research company’s stock after selling 204,158 shares during the period. CIBC World Markets Inc.’s holdings in Thermo Fisher Scientific were worth $1,869,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in TMO. Arrowstreet Capital Limited Partnership purchased a new position in Thermo Fisher Scientific in the fourth quarter valued at $1,516,000. Ninepoint Partners LP purchased a new position in Thermo Fisher Scientific in the fourth quarter valued at $285,000. Hudson Bay Capital Management LP purchased a new position in Thermo Fisher Scientific in the fourth quarter valued at $33,509,000. Derby & Company Inc. purchased a new position in Thermo Fisher Scientific in the fourth quarter valued at $1,534,000. Finally, Commerce Bank increased its holdings in Thermo Fisher Scientific by 1.6% in the fourth quarter. Commerce Bank now owns 227,763 shares of the medical research company’s stock valued at $43,248,000 after buying an additional 3,577 shares in the last quarter. 85.76% of the stock is owned by institutional investors.
TMO has been the subject of a number of recent analyst reports. Zacks Investment Research raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $240.00 price objective for the company in a report on Thursday, March 22nd. Morgan Stanley cut their price objective on shares of Thermo Fisher Scientific from $228.00 to $216.00 and set an “overweight” rating for the company in a report on Wednesday, April 11th. Finally, ValuEngine cut shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a report on Wednesday, June 20th. Two analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. Thermo Fisher Scientific currently has a consensus rating of “Buy” and a consensus target price of $224.38.
In related news, CEO Marc N. Casper sold 50,000 shares of the business’s stock in a transaction dated Wednesday, June 13th. The shares were sold at an average price of $217.71, for a total transaction of $10,885,500.00. Following the transaction, the chief executive officer now directly owns 272,122 shares in the company, valued at $59,243,680.62. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director C Martin Harris sold 206 shares of the business’s stock in a transaction dated Friday, May 18th. The stock was sold at an average price of $214.43, for a total transaction of $44,172.58. Following the transaction, the director now owns 5,106 shares in the company, valued at $1,094,879.58. The disclosure for this sale can be found here. In the last quarter, insiders sold 97,706 shares of company stock worth $21,125,673. Company insiders own 0.49% of the company’s stock.
Shares of Thermo Fisher Scientific opened at $205.16 on Wednesday, according to Marketbeat.com. Thermo Fisher Scientific Inc. has a 52-week low of $170.07 and a 52-week high of $226.44. The stock has a market capitalization of $83.98 billion, a PE ratio of 21.62, a P/E/G ratio of 1.53 and a beta of 1.11. The company has a current ratio of 1.36, a quick ratio of 0.95 and a debt-to-equity ratio of 0.69.
Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, April 25th. The medical research company reported $2.50 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.42 by $0.08. Thermo Fisher Scientific had a net margin of 10.24% and a return on equity of 16.09%. The business had revenue of $5.85 billion for the quarter, compared to analyst estimates of $5.62 billion. During the same quarter last year, the business earned $2.08 earnings per share. The company’s revenue for the quarter was up 22.8% compared to the same quarter last year. research analysts predict that Thermo Fisher Scientific Inc. will post 10.9 earnings per share for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Monday, July 16th. Stockholders of record on Friday, June 15th will be given a $0.17 dividend. The ex-dividend date is Thursday, June 14th. This represents a $0.68 annualized dividend and a dividend yield of 0.33%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 7.17%.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.